–First study extrapolates efficacy of transdermal dextroamphetamine from pediatric to adult populations– –Second study explores variations in patch wear-times– MIAMI and JERSEY CITY, N.J., Oct. 17, ...
(National) Nov. 8, 2004 - Kyle Doyle, like as much as nine percent of America's children, has Attention Deficit Hyperactivity Disorder, "I won't listen, and I don't pay attention a lot, and I talk a ...
SAN DIEGO – MAY 23, 2007 – Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today that DAYTRANA™ (methylphenidate transdermal system), its Attention Deficit Hyperactivity Disorder (ADHD) patch, ...
BOSTON – OCTOBER 25, 2007 – Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, announced that data from a 12-month study of DAYTRANATM (methylphenidate ...
NEW YORK (Reuters Health) - Smoking during pregnancy has been linked to a higher chance of the child having attention-deficit/hyperactivity disorder (ADHD), and a new ...
WASHINGTON - The FDA on Thursday approved the first skin patch to treat attention deficit hyperactivity disorder in children. Called Daytrana, the patch is designed to be worn for nine hours and ...
MIAMI and JERSEY CITY, N.J., Oct. 17, 2022 /PRNewswire/ -- Noven Pharmaceuticals. Inc., (Noven), a wholly owned subsidiary of Hisamitsu Pharmaceutical Co., Inc. focusing on the development of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results